Transcription Factor mRNA Products

product-img

Introduction Product List Product FeaturesApplication Q&A

Introduction

Transcription factors are proteins that regulate the transcriptional process of genes, containing one or more specific DNA binding domains that bind to DNA sequences in the vicinity of genes. In general, transcription factors regulate gene expression by forming a transcription initiation complex with RNA polymerase II to enhance or block the recruitment of the characteristic gene to RNA polymerase. Creative Biolabs can provide you with products that can manufacture transcription factor mRNA under a rigorous QC process and each type of transcription factor mRNA is carefully designed by our team of experts. Transcription factor mRNAs can primarily assist you in your gene therapy and related physiological studies. You can select your product from the list below according to the type of nucleoside modification, cap and tail specifications. For pre-made products, you can get the shortest lead time based on Creative Biolabs' IVTScrip™ platform, which has been optimised for fast and high volume mRNA synthesis.

Pre-made transcription factor mRNA products may not cover all transcription factors. Therefore as a complement, Creative Biolabs offers a bespoke service for specific transcription factor mRNAs. Our dedicated team of experts will develop the most suitable solution for you, including the selection of promoter systems, codon optimisation, design of nucleoside modification types, poly(A) length and 5' capsid determination. Our experts will optimise the mRNA synthesis route according to design strategy, ensuring a customised solution to your satisfaction. If you are interested in our products, please feel free to contact us.

Product List

>>>Can't find what your looking for? Contact us and we will be happy to help.

Product Features

Strict Quality Control Standards
- Multiple quality control standards.
- High stability and batch-to-batch consistency.
- Excellent purity and stability profile.
Efficient and Time-saving
- Pre-designed capping and poly (A) tail modification.
- Shorter turnaround time.

Application

Cancer Therapy: Transcription factors are often dysregulated in cancer. Delivering mRNA that encodes for transcription factors that suppress tumor growth or induce apoptosis (programmed cell death) in cancer cells can be a strategy for cancer therapy. For example, the p53 protein, a transcription factor, can induce apoptosis in cancer cells, and delivering its mRNA could help restore its function in cells where it is mutated or inactive.
Regenerative Medicine: In tissue engineering and regenerative medicine, transcription factor mRNA can be used to induce pluripotency in somatic cells or to differentiate stem cells into specific cell types needed for tissue repair. For example, the Yamanaka factors (Oct3/4, Sox2, Klf4, c-Myc) are transcription factors that can reprogram somatic cells into induced pluripotent stem cells (iPSCs), which can then be differentiated into various cell types for therapeutic purposes.
Control of Gene Expression: In research, transcription factor mRNA can be used to transiently express specific transcription factors in cells to study their roles in gene regulation, cell differentiation, and development. This approach allows scientists to dissect the complex regulatory networks governing cellular functions.
Cell Fate Conversion: Beyond regenerative medicine, transcription factor mRNA is used in basic research to study the mechanisms of cell fate conversion. By expressing specific sets of transcription factors, researchers can convert one cell type directly into another, bypassing a pluripotent state. This helps in understanding cell lineage commitments and the plasticity of the cell fate.
Drug Discovery and Screening: Transcription factor mRNA can be used in high-throughput screening assays to identify small molecules or drugs that modulate the activity of specific transcription factors. This is useful in discovering new therapeutic agents for diseases where transcription factor dysregulation plays a key role.

Q&A

Q: What controls are necessary when conducting experiments with transcription factor mRNA?

A: Essential controls include a negative control (cells treated with a non-relevant mRNA or no mRNA) to assess baseline effects, a positive control (cells treated with a known effective mRNA or treatment) to ensure the system's responsiveness, and an mRNA degradation control to confirm mRNA stability over the experiment's duration.

Q: How can you assess the transcriptional activity of a delivered transcription factor mRNA?

A: The transcriptional activity can be assessed by measuring the expression levels of target genes using quantitative PCR (qPCR), RNA sequencing (RNA-seq), or reporter assays designed to indicate the activity of the transcription factor by driving the expression of a reportable gene.

Q: What strategies can be used to target transcription factor mRNA to specific cell types?

A: Cell-specific targeting can be achieved by designing mRNA delivery systems (e.g., lipid nanoparticles, LNPs) that incorporate ligands or antibodies on their surface, which bind specifically to receptors expressed on target cells, or by utilizing tissue-specific promoters in viral vectors.

Q: How do you determine the optimal dosage of transcription factor mRNA for your experiment?

A: The optimal dosage can be determined by conducting dose-response experiments where a range of mRNA concentrations is tested for the desired biological effect. This involves measuring cell viability, protein expression levels, or the transcriptional activity of target genes to identify the concentration that achieves maximum efficacy with minimal toxicity.

Q: How do you design mRNA sequences for transcription factors?

A: Designing mRNA sequences for transcription factors involves several steps. First, you need to obtain the coding sequence (CDS) of the transcription factor of interest. This sequence must be optimized for mRNA stability and efficient translation in the target organism, which often involves codon optimization. Additionally, incorporating untranslated regions (UTRs) that enhance mRNA stability and translation efficiency, as well as a 5' cap and a poly(A) tail, is crucial for successful mRNA design.

Q: What methods are used to synthesize transcription factor mRNA?

A: Transcription factor mRNA can be synthesized in vitro using a DNA template that contains the transcription factor coding sequence. This process typically involves the use of bacteriophage RNA polymerases (such as T7, T3, or SP6) in an in vitro transcription (IVT) reaction, which also includes NTPs, a cap analog for capping the mRNA, and a poly(A) polymerase for adding a poly(A) tail.

Q: How do you ensure the purity and integrity of synthesized mRNA?

A: The purity and integrity of synthesized mRNA can be ensured through purification steps post-synthesis, such as lithium chloride precipitation, silica column-based purification, or size-exclusion chromatography. The integrity of the mRNA can be assessed using agarose gel electrophoresis or capillary electrophoresis to check for the correct size and absence of degradation products.

IVTScrip™ mRNA-Human KLF6, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WK0005MR)

Product type mRNA

Transcript KLF6

Category (CDS) Transcription Factor

Applications Gene therapy research